TY - JOUR
T1 - Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
AU - Hoste, Griet
AU - Slembrouck, Laurence
AU - Jongen, Lynn
AU - Punie, Kevin
AU - Matton, Tom
AU - Vander Borght, Sara
AU - Vanden Bempt, Isabelle
AU - Menten, Johan
AU - Wildiers, Hans
AU - Floris, Giuseppe
AU - Arteaga, Carlos
AU - Neven, Patrick
N1 - Publisher Copyright:
© 2018, Springer Nature Switzerland AG.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - We present the case of a postmenopausal patient with a secondary metastatic ER-positive, HER2-negative breast cancer who was successfully treated with fulvestrant and alpelisib following six lines of therapy. The tumour showed two uncommon PIK3CA mutations, and with the combination of alpelisib and fulvestrant the patient went from ECOG grade 3, before the start of this therapy, to ECOG grade 1 during treatment until progressive disease after 6 months. This unexpected benefit emphasizes the importance of performing a Next Generation Sequencing (NGS)-based assay to screen for several cancer genes in the metastatic setting, even after more than four lines of therapy and a high ECOG grade. Moreover, the use of alpelisib may be beneficial for uncommon PIK3CA mutations.
AB - We present the case of a postmenopausal patient with a secondary metastatic ER-positive, HER2-negative breast cancer who was successfully treated with fulvestrant and alpelisib following six lines of therapy. The tumour showed two uncommon PIK3CA mutations, and with the combination of alpelisib and fulvestrant the patient went from ECOG grade 3, before the start of this therapy, to ECOG grade 1 during treatment until progressive disease after 6 months. This unexpected benefit emphasizes the importance of performing a Next Generation Sequencing (NGS)-based assay to screen for several cancer genes in the metastatic setting, even after more than four lines of therapy and a high ECOG grade. Moreover, the use of alpelisib may be beneficial for uncommon PIK3CA mutations.
UR - http://www.scopus.com/inward/record.url?scp=85053243452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053243452&partnerID=8YFLogxK
U2 - 10.1007/s40261-018-0696-3
DO - 10.1007/s40261-018-0696-3
M3 - Article
C2 - 30187361
AN - SCOPUS:85053243452
SN - 1173-2563
VL - 38
SP - 1071
EP - 1075
JO - Clinical Drug Investigation
JF - Clinical Drug Investigation
IS - 11
ER -